Alrex®
Loteprednol 0.2% · ophthalmic suspension
Allergy, Steroid
Approved uses
Seasonal allergic conjunctivitis
1 drop in the affected eye(s) QID
Itching and injection begin easing about 2 hours after the first drop, improving through day 14.
Contraindications
- Most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella
- Mycobacterial infection of the eye
- Fungal diseases of ocular structures
- Known or suspected hypersensitivity to any ingredient of the preparation or to other corticosteroids
Ophthalmic suspension, 0.2% (loteprednol etabonate 2 mg/mL), 5 mL in a 7.5 mL bottle, 10 mL in a 10 mL bottle
There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. They are thought to act by inducing phospholipase A2 inhibitory proteins (lipocortins), postulated to control the biosynthesis of prostaglandins and leukotrienes by inhibiting release of their common precursor, arachidonic acid. Corticosteroids inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary and fibroblast proliferation, collagen deposition, and scar formation, and probably delay or slow healing. Loteprednol etabonate lacks the number 20 position ketone group and is highly lipid soluble. In preclinical studies, it undergoes extensive metabolism to inactive carboxylic acid metabolites. In a study of 0.5% loteprednol etabonate, plasma levels of drug and primary metabolite stayed below 1 ng/mL, suggesting limited systemic absorption with ALREX.
Warnings & Precautions
- IOP elevation and glaucoma: Prolonged corticosteroid use may produce glaucoma with optic nerve damage and defects in visual acuity and visual fields; monitor IOP if used 10 days or longer, and use with caution in the presence of glaucoma.
- Posterior subcapsular cataract: Prolonged corticosteroid use may produce it.
- Secondary ocular infection: Prolonged use may suppress the host response and thus increase the hazard of secondary ocular infections; in acute purulent conditions steroids may mask infection or enhance existing infection.
- Viral infection exacerbation: Ocular steroids may prolong the course and worsen the severity of many ocular viral infections including herpes simplex; a history of herpes simplex requires great caution.
- Fungal infections of the cornea: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use, and fungal cultures should be taken when appropriate.
- Corneal or scleral perforation: In diseases causing thinning of the cornea or sclera, perforations have occurred with topical steroids.
- Examination with magnification: Initial prescription and renewal beyond 14 days only after examination with magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining; re-evaluate if signs and symptoms fail to improve after two days.
- Benzalkonium chloride absorption by soft contact lenses: Do not wear a contact lens while the eye is red, and do not use this product for contact lens related irritation; when the eye is not red, wait at least ten minutes after instillation before inserting soft lenses, since the benzalkonium chloride 0.01% preservative may be absorbed by soft contact lenses.
- Contamination: Do not allow the dropper tip to touch any surface, as this may contaminate the suspension. If redness or itching becomes aggravated, consult a physician.
Common Side Effects
In clinical studies of loteprednol etabonate 0.2% to 0.5%, ocular reactions in 5% to 15% of patients included abnormal vision or blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora, foreign body sensation, itching, injection, and photophobia. Ocular reactions in less than 5% included conjunctivitis, corneal abnormalities, eyelid erythema, keratoconjunctivitis, ocular irritation, pain or discomfort, papillae, and uveitis; some were similar to the underlying ocular disease being studied. Non-ocular reactions (headache, rhinitis, pharyngitis) occurred in less than 15%. With ALREX, an IOP rise of 10 mm Hg or more occurred in 1% (1/133) versus 1% (1/135) on placebo. In loteprednol etabonate studies of 28 days or longer, it occurred in 2% (15/901), versus 7% (11/164) on 1% prednisolone acetate and 0.5% (3/583) on placebo.
Pregnancy: No adequate and well controlled studies in pregnant women. Oral dosing in rabbits during organogenesis at 3 mg/kg/day (85 times the maximum daily clinical dose) was embryotoxic (delayed ossification) and teratogenic (meningocele, abnormal left common carotid artery, limb flexures) without maternal toxicity; NOEL 0.5 mg/kg/day. Oral rat dosing gave teratogenicity from 5 mg/kg/day and embryotoxicity at higher doses. Use only if the potential benefit justifies the potential fetal risk.
Lactation: Whether topical ophthalmic dosing yields detectable quantities in human milk is unknown. Systemic steroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects; use with caution in a nursing woman.
Safety and effectiveness in pediatric patients have not been established.